Affiliation:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University (Sechenov University)
Abstract
Background. A glycoside derivative of indolocarbazole LHS-1269, one of the new drugs selectively affecting tumors, which was first synthesized at the N.N. Blokhin National Medical-Research Center of Oncology of the Ministry of Health of Russia, is of particular scientific interest. Experimental studies demonstrated a multi-target mechanism of action of this compound. LHS-1269 interacts with several intracellular targets and induces various pathways of cell death. Several innovative models of the dosage forms were designed to achieve the highest antitumor activity of the compound and to perform further preclinical studies.Aim. To develop the methods for the quantitative determination of LHS-1269 in pharmaceutical compositions proposed as a result of the search for the optimal dosage form.Materials and methods. The study analyzed the spectrophotometric characteristics of LHS-1269 solutions in dimethylformamide, dimethylsulfoxide (DMSO) and in the mixture of solvents DMSO–ethyl alcohol, as well as electronic absorption spectra of the excipients in the mixture of solvents DMSO–ethyl alcohol. Spectrophotometric measurements were performed on a Cary 100 spectrophotometer (Varian, Inc., Australia) in the wavelength range from 200 to 500 nm. The standard sample is the substance LHS-1269 (N.N. Blokhin Oncology Research Center of the Ministry of Health of Russia).Results. The carried out studies showed that LHS-1269 solutions in dimethylformamide, DMSO and mixture of DMSO– ethyl alcohol are suitable for spectrophotometric measurements. Several variants of the methodology for the assay of LHS-1269 in various dosage form models that differ in the content of the active substance and the excipients composition have been developed: LHS-1269 concentrate for solution for injection and infusion; lyophilisate for solution for injection; liposomal lyophilisate for dispersion for injection.Conclusion. Techniques for the assay of LHS-1269 in dosage form models have been developed. It has been shown that the developed techniques are applicable for LHS-1269 quantitative determination in innovative dosage forms containing polymeric low molecular weightsolubilizers, lipids, cholesterol, mono- or oligosaccharides as excipients.
Publisher
Publishing House ABV Press
Reference21 articles.
1. Janosik T., Rannug A., Rannug U. et al. Chemistry and properties of indolocarbazoles. Chem Rev 2018;118(18):9058–128. DOI: 10.1021/acs.chemrev.8b00186
2. Zenkov R.G., Ektova L.V., Vlasova O.A. et al. Indolo[2,3-a]carbazoles: diversity, biological properties, application in antitumor therapy. Chem Heterocycl Compd 2020;56(6):644–58. DOI: 10.1007/s10593-020-02714-4
3. Lantsova A.V., Sanarova E.V., Oborotova N.A. et al. Development of technology for injectable dosage form based on the national substance from the class of indolocarbazoles – LHS-1208. Rossiyskiy bioterapevticheskiy zhurnal = Russian Journal of Biotherapy 2014;13(3):25–32. (In Russ.).
4. Golubeva I.S., Eremina V.A., Moiseeva N.I. et al. A derivative of the class of N-glycosides indolo[2,3-a]pyrrolo[3,4-c] carbazole-5,7-diones-N-{2-(β-d-xylo-pyranosyl)-5,7-dioxoindolo[2,3-a]pyrrolo[3,4-c]carbazole-6-yl}pyridine-2-carboxamide with cytotoxic and antitumor activity. Patent RU No. 2667906 dated 11.09.2017. (In Russ.).
5. Ektova L.V., Eremina V.A., Tikhonova N.I. еt al. Synthesis and cytotoxicity of N-glycosides of indolo[2,3-а]pyrrolo[3,4-c] carbazolo-5,7-diones substituted at the maleimide nitrogen atom. Khimiko-farmatsevticheskiy zhurnal = Chemical and Pharmaceutical Journal 2020;54(5):26–9. (In Russ.). DOI: 10.30906/0023-1134-2020-54-5-26-29
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献